Document is current
Any future updates will be listed below
-
Authors
Vreeland, Timothy J.
Clifton, Guy T.
Hale, Diane F.
Chick, Robert C.
Hickerson, Annelies T.
Cindass, Jessica L.
Adams, Alexandra M.
Bohan, Phillip M. Kemp
Andtbacka, Robert H. I.
Berger, Adam C.
Jakub, James W.
Sussman, Jeffrey J.
Terando, Alicia M.
Wagner, Thomas
Peoples, George E.
Faries, Mark B.
-
Funding
Funding for this research was provided by:
Elios Therapeutics
- License Information
-
More Information
Article History
Received: 25 September 2020
Accepted: 25 January 2021
First Online: 27 February 2021
Disclosures
: This clinical study was sponsored by Elios Therapeutics, a wholly-owned subsidiary of Perseus Holdings, USA. which provided funding to the institution of Dr. Robert Andtbacka; Dr. James Jakub is a Advisory Board Member of a Melanoma Surgical Advisory Board, Norvartis Oncology; Dr. Thomas Wagner is an employee of Orbis Health Solutions; Dr. George Peoples is a part-time employeed of Orbis Health Solutions, has consulted for a number of companies broadly in the cancer vaccine space (none working in melanoma or with autologous DC-based vaccines), and has multiple patents for different versions of cancer vaccines, mostly peptide-based vaccines; Dr. Wagner is the inventor on several patents on the technology of the study. Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Robert C. Chick, Annelies T. Hickerson, Jessica L. Cindass, Alexandra M. Adams, Phillip M. Kemp Bohan, Adam C. Berger, Jeffrey J. Sussman, Alicia M. Terando, and Mark B. Faries have no conflicts of interest to declare.
Free to read: This content has been made available to all.
